Key result
Twice-daily aspirin reduces serum thromboxane B2 by ~79% vs once-daily in essential thrombocythemia.
Why the study?
In essential thrombocythemia, once-daily low-dose aspirin is recommended, but accelerated platelet generation may shorten platelet COX-1 inhibition.
Does twice-daily or thrice-daily aspirin 100 mg improve platelet COX-1 inhibition compared to once-daily dosing in patients with essential thrombocythemia?
RCT (n=245)
Double-blind
1:1:1
Yes
Does twice-daily or thrice-daily aspirin 100 mg improve platelet COX-1 inhibition compared to once-daily dosing in patients with essential thrombocythemia?
Shortening the aspirin dosing interval to 12 hours (twice daily) markedly improves platelet COX-1 inhibition in patients with essential thrombocythemia compared to the standard once-daily regimen.
Answers are grounded in this paper and cite their sources.
Twice-daily aspirin improves platelet COX-1 inhibition in ET; challenges once-daily as standard and supports regimen reevaluation in practice.
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet cyclooxygenase-1 (COX-1) inhibition. We performed a multicenter double-blind trial to investigate the efficacy of 3 aspirin regimens in optimizing platelet COX-1 inhibition while preserving COX-2-dependent vascular thromboresistance. Patients on chronic once-daily low-dose aspirin (n = 245) were randomized (1:1:1) to receive 100 mg of aspirin 1, 2, or 3 times daily for 2 weeks. Serum thromboxane B2 (sTXB2), a validated biomarker of platelet COX-1 activity, and urinary prostacyclin metabolite (PGIM) excretion were measured at randomization and after 2 weeks, as primary surrogate end points of efficacy and safety, respectively. Urinary TX metabolite (TXM) excretion, gastrointestinal tolerance, and ET-related symptoms were also investigated. Evaluable patients assigned to the twice-daily and thrice-daily regimens showed substantially reduced interindividual variability and lower median (interquartile range) values for sTXB2 (ng/mL) compared with the once-daily arm: 4 (2.1-6.7; n = 79), 2.5 (1.4-5.65, n = 79), and 19.3 (9.7-40; n = 85), respectively. Urinary PGIM was comparable in the 3 arms. Urinary TXM was reduced by 35% in both experimental arms. Patients in the thrice-daily arm reported a higher abdominal discomfort score. In conclusion, the currently recommended aspirin regimen of 75 to 100 once daily for cardiovascular prophylaxis appears to be largely inadequate in reducing platelet activation in the vast majority of patients with ET. The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosing interval to 12 hours, with no improvement with further reductions (EudraCT 2016-002885-30).
No takes yet. Share an insight, caveat, or question.
Rocca et al. (2020) conducted an RCT in Essential thrombocythemia (n=245). Aspirin vs. 100 mg once daily was evaluated on Serum thromboxane B2 (sTXB2) and urinary prostacyclin metabolite (PGIM) excretion. In patients with essential thrombocythemia, shortening the aspirin dosing interval to twice daily reduced median serum thromboxane B2 from 19.3 ng/mL to 4 ng/mL compared with once daily.
Synapse has enriched 10 related papers. Consider them for comparative context: